Chemoprophylaxis with tafenoquine is safe and effective for preventing malaria in healthy non-immune individuals challenged with blood stage P falciparum.
Placental malaria has a profound effect on the fetal immune system, and prenatal malaria exposure categories may drive heterogeneity to malaria susceptibility.
Iron deficiency may protect African children against malaria infection when defined using ferritin and transferrin saturation.
A natural variability of genotype-determined, CYP2D6-dependent metabolism of primaquine phosphate is associated with an increased risk of failure in the treatment of P vivax malaria.
Chloroquine with either 7- or 14-day primaquine regimens provided highly effective radical cure of vivax malaria on the Thailand-Myanmar border.
Long-lasting insecticidal nets treated with permethrin plus pyriproxyfen are more effective in preventing clinical malaria compared with standard insecticidal nets.
A malaria transmission-blocking vaccine, Pfs25H-EPA in Alhydrogel®, was well tolerated and safe and induced significant blockage of parasite transmission, but this activity was only seen at peak titers after 4 vaccine doses.
In clinical trials, tafenoquine, an 8-aminoquinoline, demonstrated efficacy against 2 primary types of malaria, Plasmodium vivax and P. falciparum malaria.
The FDA approved Krintafel for the radical cure of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P vivax infection.
Early findings show that the P27A candidate vaccine for malaria prevention appeared to be safe and induced a strong immunogenic response with parasite growth inhibitory capacity.
The benefits of using slowly eliminated chloroquine vs rapidly eliminated arsenuate anti-malarials were assessed in a 3-way randomized comparison trial.
As a direct consequence of this trial, WHO revised its policy on long-lasting insecticidal nets in September, 2017, gave interim endorsement to pyrethroid-piperonyl butoxide nets as a new WHO class of vector control product.
In some locations, malaria incidence remained high despite high use of nets, emphasizing the need for new tools and approaches for malaria prevention if targets for the reduction of the global malaria burden are to be achieved.
Women in the United States with uncomplicated malaria during the first trimester of pregnancy should be treated with the currently recommended options of either mefloquine or quinine plus clindamycin. However, when neither of these options is available, artemether-lumefantrine should be considered for treatment.
First trimester treatment for malaria could change with the results of 1 of the most robust meta-analyses to date that compared artemisinin-based therapy vs quinine.
As long-term neurocognitive deficits can occur as a result of severe malaria, researchers assessed the potential neuroprotective effect of inhaled nitric oxide on children with the infection.
Without proactive measures and response, the changing climate is projected to continue to adversely affect the global incidence and distribution of infectious diseases and cause 250,000 additional deaths per year between 2030 and 2050.
The FDA granted orphan drug designation to an investigational treatment for malaria.
Mass drug administration has been proposed as a method to eradicate Plasmodium falciparum malaria.
Placental malaria during pregnancy may raise the risk of malaria infection in childhood by promoting maternal microchimerism, in which the fetus acquires noninherited maternal cells during pregnancy. Maternal microchimerism may be the mechanism by which the fetus develops tolerance to malaria antigens, leading to an impaired malaria-specific immune response.
3 IV doses of PfSPZ vaccine conferred protection after immunization against different Pf strains of malaria than the one the vaccine came from.
Investigational vaccine is designed to trigger an immune response to mosquito saliva rather than to a specific virus or parasite carried by mosquitoes.
In an animal model study, researchers tested an antibody therapy that may treat cerebral malaria.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Predicative Factors for Relapse in Adult Bacterial Osteomyelitis
- Zika Vaccine Cost-Effective for Young Adults and Childbearing-Age Women
- Cefiderocol for the Treatment of Complicated Gram-Negative UTIs
- Stethoscope Cleaning Standards May Not Eliminate Bacterial Contamination
- Higher Viral Control in Women With HIV in Serodiscordant Relationships
- Antibiotic Use in Neonatal Settings in Need of Improvement
- Shorter Antibiotic Course Noninferior for Gram-Negative Bacteremia
- Rapid Antimicrobial Susceptibility Testing on Urine Directly Accelerates Results
- Antibiotics May Be Beneficial in Children With Prolonged Wet Cough
- Emergency Department Overcrowding Associated With Delayed Antibiotics in Patients With Sepsis
- Bacteria Bystanders Play Important Role in Antibiotic Resistance Development
- Many New Cancer Patients Unaware of Their Hepatitis Status
- Worse Outcomes in Community-Acquired Pneumonia Linked to Higher FGF21 Levels
- Bacterial Pneumonia-Complicating Influenza: Risks, Morbidity, and Mortality
- Bexsero Vaccine Has Potential for Cross-Protection Against Gonorrhea